FDA Brief

Warning letters Drugs

FDA warning letter to

Grupo Yacana Mexico, S.A.S. de C.V.

High riskIssued Jan 26, 2021Posted Feb 2, 2021Center for Drug Evaluation and Research | CDER

Grupo Yacana Mexico's hand sanitizers were refused at the U.S. border after FDA found methanol substitution and low active ingredient.

What happened

FDA found the problems after YACANA hand sanitizers labeled as made at Grupo Yacana Mexico were detained and refused admission at the U.S. border. FDA laboratory testing of detained batches found methanol in products labeled as ethanol hand rub, including 49% to 63% methanol, and found one product labeled as isopropyl alcohol hand rub contained 53% ethanol and 0% isopropyl alcohol. Another isopropyl alcohol batch contained 61% isopropyl alcohol although labeled 70%.

What FDA found

  1. Batches labeled to contain 70% ethanol contained methanol at 49% to 63% and very low ethanol.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. One batch labeled to contain 70% isopropyl alcohol contained 53% ethanol and no isopropyl alcohol.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  3. Another batch labeled to contain 70% isopropyl alcohol contained only 61% isopropyl alcohol.

    FD&C Act section 501(c), 21 U.S.C. 351(c)
  4. The substitution and low potency show quality assurance was not working under CGMP (current good manufacturing practice).

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. The hand sanitizers were unapproved new drugs and did not meet the tentative final monograph or section 505G conditions.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d); section 505G, 21 U.S.C. 355h
  6. Labels were false or misleading, omitted methanol or ethanol, and made the products misbranded.

    FD&C Act sections 502(a), (e), (ee), and (j), 21 U.S.C. 352(a), (e), (ee), and (j)

What FDA wants

FDA asks the company to investigate how the substitutions and low potency happened and to provide raw material supplier details, U.S.-shipped batch lists, distribution reconciliation, and complete batch records. It asks for a written response within 15 working days and recommends a qualified CGMP consultant if the firm resumes U.S. drug manufacturing.

Who should pay attention

  • distributors and retailers that sold YACANA hand sanitizers
  • brands that use contract manufacturers for OTC hand sanitizers
  • consumers and health care buyers relying on labeled alcohol content

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk